Advances in immunotherapy for non-small cell lung cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 205-208, 2018.
Article
Dans Chinois
| WPRIM
| ID: wpr-706780
ABSTRACT
The theory of tumor immunity has gone through more than a century of exploration and shown remarkable clinical efficacy. Therapy based on targeting immune checkpoints,especially anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibody monotherapy,has made significant progress in the treatment of advanced lung cancer.Consequently,the discovery of new immune checkpoints has be-come an area of interest.Additionally,combined immunotherapy is expected to be the future direction of immunotherapy.However, at this stage,immunotherapy has not yet resulted in widespread benefit.Identifying immune resistance mechanisms will further pro-mote individualized treatment.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Clinical Oncology
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS